Company intelligence / Profile preview

Hengrui Yuanzheng

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Hengrui Yuanzheng is a clinical-stage biotechnology company focused on the development of innovative adoptive cell therapies for the treatment of cancer. As a specialized subsidiary of Jiangsu Hengrui Pharmaceuticals, the company leverages advanced technology platforms in CAR-T, TCR-T, and NK cell therapies to address unmet needs in both liquid and solid tumors. Its most advanced programs target hepatocellular carcinoma using AFP-specific TCR-T cells and GPC3-targeted CAR-T cells. Hengrui Yuanzheng is recognized for its integrated capabilities in cell therapy research, clinical development, and GMP-compliant manufacturing.

Therapeutic areas: Oncology
Modalities: Cell therapyCAR-T cell therapyT cell receptor engineered T cell therapyNK cell therapy
Industry: Biotech

Partnerships

Jiangsu Hengrui Pharmaceuticals

Beyond the preview

Go deeper on Hengrui Yuanzheng.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hengrui Yuanzheng.

Explore the full profile